Trius Therapeutics Inc 4/A
4/A · Trius Therapeutics Inc · Filed Jun 11, 2013
Insider Transaction Report
Form 4/AAmended
Finn John
Chief Scientific Officer
Transactions
- Sale
Common Stock
2013-05-10$7.47/sh−3,000$22,425→ 186,860 total(indirect: By Trust)
Holdings
- 1,782
Common Stock
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 21, 2012
- [F2]The weighted average sales price for the transaction reported was $7.475, and the range of prices were between $7.10 and $7.55. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided
- [F3]This Form 4 is being amended to correctly reflect the holdings as indirectly held.
- [F4]This Form 4 is being amended to include direct holdings which were inadvertently omitted from the filing.